AURA
Aura Biosciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Aura Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
+4.42%
vs ±83.3% implied · ×0.05
shaded = implied · ▲▼ = realized
Aura Biosciences, Inc.
6.64
+0.40 · +6.49%
post 6.64 0.00%
| Manager | Value | % base | |
|---|---|---|---|
| TCG Crossover | $67.7M | 9.98% | new |
| Suvretta | $51.2M | 7.54% | +64.79% |
| Frazier Life Sciences | $50.4M | 7.43% | +39.22% |
| Long Focus | $36.3M | 5.36% | +10.82% |
| BlackRockindex-like | $33.4M | 4.93% | +31.26% |
| Manager | Value | % base | |
|---|---|---|---|
| TCG Crossover | $67.7M | 9.98% | new |
| Suvretta | $51.2M | 7.54% | +64.79% |
| Frazier Life Sciences | $50.4M | 7.43% | +39.22% |
| Long Focus | $36.3M | 5.36% | +10.82% |
| BlackRockindex-like | $33.4M | 4.93% | +31.26% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Aura Biosciences, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Aura Biosciences, Inc.'s 6 closest co-movers, none share that code.
Bull2
Bear2
Tall tick = annual report · Source: EDGAR
Expected move
Inputsspot 8.00exp Nov 20ATM strike 8ATM straddle 5.00IV 416%